公开(公告)号：US09981031B2

公开(公告)日：2018-05-29

申请号：US15240385

申请日：2016-08-18

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Paolo Costantino

IPC: A61K39/095 ,  A61K39/385 ,  A61K39/00 ,  A61K39/116 ,  C07K14/22 ,  A61K9/00 ,  A61K39/08 ,  A61K39/102 ,  A61K39/09 ,  A61K39/05 ,  A61K39/29 ,  A61K39/02 ,  A61K39/12

CPC classification number: A61K39/095 ,  A61K9/0019 ,  A61K39/0017 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/092 ,  A61K39/099 ,  A61K39/102 ,  A61K39/116 ,  A61K39/12 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/62 ,  A61K2039/627 ,  A61K2039/70 ,  C07K14/22

Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises

公开(公告)号：US09839686B2

公开(公告)日：2017-12-12

申请号：US14612111

申请日：2015-02-02

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Francesco Berti ,  Paolo Costantino ,  Maria Rosaria Romano

IPC: A61K39/385 ,  A61K39/085 ,  A61K31/70 ,  A61K47/48 ,  A61K47/64 ,  A61K39/00

CPC classification number: A61K39/385 ,  A61K39/085 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/627 ,  Y10S424/831 ,  Y10S530/807

Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.

公开(公告)号：US10716841B2

公开(公告)日：2020-07-21

申请号：US15339741

申请日：2016-10-31

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Paolo Costantino

IPC: A61K39/095 ,  A61K45/00 ,  A61K47/00 ,  A61K39/00 ,  C09F1/00 ,  A23J1/04 ,  A61K38/00 ,  A23J1/20 ,  C07H15/04 ,  A61K39/09 ,  C07K14/22 ,  C07K14/285 ,  A61K38/48 ,  A61K39/102 ,  A61K39/39 ,  C09G1/00

Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of Men A saccharide:MenC saccharide is >1.

公开(公告)号：US10736959B2

公开(公告)日：2020-08-11

申请号：US15809524

申请日：2017-11-10

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Francesco Berti ,  Paolo Costantino ,  Maria Rosaria Romano

IPC: A61K47/64 ,  A61K39/085 ,  A61K39/385 ,  A61K39/00

Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.

公开(公告)号：US10668142B2

公开(公告)日：2020-06-02

申请号：US15962507

申请日：2018-04-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Paolo Costantino

IPC: A61K39/095 ,  A61K9/00 ,  C07K14/22 ,  A61K39/08 ,  A61K39/116 ,  A61K39/05 ,  A61K39/385 ,  A61K39/00 ,  A61K39/102 ,  A61K39/09 ,  A61K39/29 ,  A61K39/02 ,  A61K39/12

Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises

公开(公告)号：US10172928B2

公开(公告)日：2019-01-08

申请号：US15536132

申请日：2015-12-17

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Francesco Berti ,  Paolo Costantino ,  Maria Rosaria Romano

IPC: G01N1/18 ,  A61K39/09 ,  C08B37/00

Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.

公开(公告)号：US09441004B2

公开(公告)日：2016-09-13

申请号：US14714097

申请日：2015-05-15

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Paolo Costantino ,  Maria Rosaria Romano ,  Francesco Berti

IPC: A61K47/48 ,  A61K39/00 ,  C07H1/08 ,  C12P19/04 ,  A61K39/085

CPC classification number: C07H1/08 ,  A61K39/085 ,  A61K2039/55505 ,  A61K2039/6037 ,  C12P19/04

Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.

Abstract translation: 本发明提供了一种从金黄色葡萄球菌5型或8型细胞中释放荚膜多糖的方法，包括用酸处理细胞的步骤。 本发明还提供了一种从包括该方法的金黄色葡萄球菌5型或8型细胞中纯化荚膜多糖的方法。 其他处理步骤可以包括在该方法中，例如酶处理，例如， 去除核酸，蛋白质和/或肽聚糖污染物; 渗滤，例如 去除低分子量污染物; 阴离子交换层析，例如 去除残留蛋白质; 和集中。